These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 17722224)

  • 1. Rituximab for refractory polymyositis: an open-label prospective study.
    Mok CC; Ho LY; To CH
    J Rheumatol; 2007 Sep; 34(9):1864-8. PubMed ID: 17722224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab treatment in patients with refractory inflammatory myopathies.
    Mahler EA; Blom M; Voermans NC; van Engelen BG; van Riel PL; Vonk MC
    Rheumatology (Oxford); 2011 Dec; 50(12):2206-13. PubMed ID: 21571768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate.
    Hengstman GJ; De Bleecker JL; Feist E; Vissing J; Denton CP; Manoussakis MN; Slott Jensen H; van Engelen BG; van den Hoogen FH
    Eur Neurol; 2008; 59(3-4):159-63. PubMed ID: 18230873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab in the treatment of dermatomyositis: an open-label pilot study.
    Levine TD
    Arthritis Rheum; 2005 Feb; 52(2):601-7. PubMed ID: 15692974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot trial of rituximab in the treatment of patients with dermatomyositis.
    Chung L; Genovese MC; Fiorentino DF
    Arch Dermatol; 2007 Jun; 143(6):763-7. PubMed ID: 17576943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures.
    Adams EM; Pucino F; Yarboro C; Hicks JE; Thornton B; McGarvey C; Sonies BC; Bartlett ML; Villalba ML; Fleisher T; Plotz PH
    J Rheumatol; 1999 Feb; 26(2):352-60. PubMed ID: 9972969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab as therapy for refractory polymyositis and dermatomyositis.
    Noss EH; Hausner-Sypek DL; Weinblatt ME
    J Rheumatol; 2006 May; 33(5):1021-6. PubMed ID: 16541475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency virus-associated polymyositis: a longitudinal study of outcome.
    Johnson RW; Williams FM; Kazi S; Dimachkie MM; Reveille JD
    Arthritis Rheum; 2003 Apr; 49(2):172-8. PubMed ID: 12687507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis.
    Keystone E; Fleischmann R; Emery P; Furst DE; van Vollenhoven R; Bathon J; Dougados M; Baldassare A; Ferraccioli G; Chubick A; Udell J; Cravets MW; Agarwal S; Cooper S; Magrini F
    Arthritis Rheum; 2007 Dec; 56(12):3896-908. PubMed ID: 18050221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.
    Dastmalchi M; Grundtman C; Alexanderson H; Mavragani CP; Einarsdottir H; Helmers SB; Elvin K; Crow MK; Nennesmo I; Lundberg IE
    Ann Rheum Dis; 2008 Dec; 67(12):1670-7. PubMed ID: 18272672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series.
    Sem M; Molberg O; Lund MB; Gran JT
    Rheumatology (Oxford); 2009 Aug; 48(8):968-71. PubMed ID: 19531628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.
    Mease PJ; Revicki DA; Szechinski J; Greenwald M; Kivitz A; Barile-Fabris L; Kalsi J; Eames J; Leirisalo-Repo M
    J Rheumatol; 2008 Jan; 35(1):20-30. PubMed ID: 18050385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.
    Dass S; Bowman SJ; Vital EM; Ikeda K; Pease CT; Hamburger J; Richards A; Rauz S; Emery P
    Ann Rheum Dis; 2008 Nov; 67(11):1541-4. PubMed ID: 18276741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of a sixteen-week training program on strength, pain, and function in rheumatoid arthritis patients.
    Flint-Wagner HG; Lisse J; Lohman TG; Going SB; Guido T; Cussler E; Gates D; Yocum DE
    J Clin Rheumatol; 2009 Jun; 15(4):165-71. PubMed ID: 19279507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy.
    Gonzalez-Juanatey C; Llorca J; Vazquez-Rodriguez TR; Diaz-Varela N; Garcia-Quiroga H; Gonzalez-Gay MA
    Arthritis Rheum; 2008 Dec; 59(12):1821-4. PubMed ID: 19035415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of rituximab on resistant SLE disease including lung involvement.
    Reynolds JA; Toescu V; Yee CS; Prabu A; Situnayake D; Gordon C
    Lupus; 2009 Jan; 18(1):67-73. PubMed ID: 19074171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Refractory dermatomyositis associated with chronic organizing pneumonia treated with rituximab: report of one case].
    Yáñez V J; Cisternas M M; Saldías H V; Saldías P F
    Rev Med Chil; 2009 Jan; 137(1):88-93. PubMed ID: 19399327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept.
    Boonen A; Patel V; Traina S; Chiou CF; Maetzel A; Tsuji W
    J Rheumatol; 2008 Apr; 35(4):662-7. PubMed ID: 18278836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of rituximab in refractory polymyositis.
    Lambotte O; Kotb R; Maigne G; Blanc FX; Goujard C; Delfraissy JF
    J Rheumatol; 2005 Jul; 32(7):1369-70. PubMed ID: 15996082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis.
    van der Kooij SM; de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Ewals JA; Han KH; Hazes JM; Kerstens PJ; Peeters AJ; van Zeben D; Breedveld FC; Huizinga TW; Dijkmans BA; Allaart CF
    Arthritis Rheum; 2009 Jan; 61(1):4-12. PubMed ID: 19116965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.